Dr. Mohammad T. Al-assi, M.D.
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Years since graduation
- 40
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 292
Licensed in Texas since 1993, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
TX license J4684 (first issued 1993; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Texas Health Arlington Memorial Hospital Arlington, TX
Medical groups
- Texas Digestive Disease Consultants, PLLC (608 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 292
- Services billed
- 2,196
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 127 | 106 |
| Established patient office or other outpatient visit, 30-39 minutes | 100 | 83 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 93 | 40 |
| Biopsy of large bowel using a flexible endoscope | 76 | 76 |
| Insertion of guide wire with dilation of esophagus using a flexible endoscope | 52 | 44 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 46 | 13 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 42 | 42 |
| Established patient office or other outpatient visit, 20-29 minutes | 33 | 32 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 31 | 30 |
| New patient office or other outpatient visit, 45-59 minutes | 29 | 29 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pantoprazole Sodium Other prescribers in Arlington, TX | 525 |
| Omeprazole Other prescribers in Arlington, TX | 344 |
| Sucralfate Other prescribers in Arlington, TX | 245 |
| Dicyclomine Hcl Other prescribers in Arlington, TX | 165 |
| Linzess (linaclotide) Other prescribers in Arlington, TX | 83 |
| Colestipol Hcl Other prescribers in Arlington, TX | 66 |
| Famotidine Other prescribers in Arlington, TX | 41 |
| Diphenoxylate-Atropine (diphenoxylate hcl/atropine) Other prescribers in Arlington, TX | 38 |
| Promethazine Hcl Other prescribers in Arlington, TX | 34 |
| Ondansetron Odt (ondansetron) Other prescribers in Arlington, TX | 33 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 27 payments worth $542 in total to this clinician.
| AbbVie Inc. | $112 |
|---|---|
| Janssen Biotech, Inc. | $69.92 |
| Takeda Pharmaceuticals U.S.A., Inc. | $67.72 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.47 |
| Lilly USA, LLC | $57.66 |
| Celltrion USA Inc. | $45.24 |
| Ardelyx, Inc. | $40.80 |
| Ipsen Biopharmaceuticals, Inc | $31.11 |
| Food and Beverage | $542 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 2 companies. The companies reported $21,158 in research payments for these studies, mostly to the institutions running them.
- M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433
AbbVie Inc. - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
AbbVie Inc. · Active, not recruiting · NCT03006068 - M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
AbbVie Inc. - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
AbbVie Inc. · Active, not recruiting · NCT03345823 - An openlabel extension study of etrasimod in subjects with moderately to severely active ulcerative colitis
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.